<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368185">
  <stage>Registered</stage>
  <submitdate>16/03/2015</submitdate>
  <approvaldate>15/05/2015</approvaldate>
  <actrnumber>ACTRN12615000487516</actrnumber>
  <trial_identification>
    <studytitle>A pilot study of the effect of oral curcumin on lymphocyte count in patients with clinical stage 0/1 chronic lymphocytic leukemia. </studytitle>
    <scientifictitle>A pilot study of the effect of oral curcumin on lymphocyte count in patients with clinical stage 0/1 chronic lymphocytic leukemia. </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>stage 0/1 chronic lymphocytic leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Curcumin, derived from the spice turmeric, has anticancer and anti-inflammatory properties. Curcumin will be administered orally at a dose of 2g/day. Patients will be monitored at 2 monthly intervals for a period of six months. Blood samples will be collected at each visit. Lymphocyte count,  surface leukocyte markers,CRP and ESR, liver function will be assessed by blood tests. Compliance will be ascertained by questioning the patient.  </interventions>
    <comparator>This is a pilot study of a GRAS nutraceutical and thus no comparator group is involved in the study.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A change in absolute lymphocyte count as assessed by serum assay. </outcome>
      <timepoint>assessment will be made at baseline, 2, 4 and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>a change in surface leukocyte markers as determined by blood tests.</outcome>
      <timepoint>assessment will be made at baseline, 2, 4 and 6 months. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CRP and ESR as determined by blood tests</outcome>
      <timepoint>baseline, 2, 4 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>liver function as determined by blood tests</outcome>
      <timepoint>baseline, 2, 4 and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or female patients over the age of 40 who have been diagnosed with stage 0/1 chronic lymphocytic leukemia (absolute lymphocyte count &gt; 20x10 (9)lymphocytes/L). 	</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1)Patients who are being actively treated. 
2)Requirement for major surgery
3) Patients with diabetes
4) Patients on warfarin
5) Patients with GORD	
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>3/06/2013</anticipatedstartdate>
    <actualstartdate>28/10/2013</actualstartdate>
    <anticipatedenddate>2/06/2014</anticipatedenddate>
    <actualenddate>28/10/2014</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>21</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St George Hospital - Kogarah</hospital>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Southern Sydney Haematology</primarysponsorname>
    <primarysponsoraddress>1-5 Derby street, Kogarah, NSW, 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Researchers Department
St George Hospital</fundingname>
      <fundingaddress>St George Hospital
Gray street
Kogarah
NSW
2217</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Department of Endocrinology
Prichard Wing
St George Hospital
</sponsorname>
      <sponsoraddress>Prichard Wing
St George Hospital
Gray street 
Kogarah
NSW
2217</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine if curcumin can delay progression of chronic lymphocytic leukemia in patients with early disease. Who is it for? You may be eligible join this study if you are a patient over the age of 40 who has been diagnosed with stage 0/1 chronic lymphocytic leukemia (absolute lymphocyte count &gt; 20x10^9 lymphocytes/L). Trial details All participants in this trial will be given curcumin (derived from the spice turmeric) orally at a dose of 2g/day for 6 months. Participants will be assessed by blood test every 2 months over the 6 month study period in order to determine treatment response such as absolute change in lymphocyte count. 
</summary>
    <trialwebsite />
    <publication>Publication: The effect of curcumin (as Meriva) on absolute lymphocyte count (ALC), NK cells and T cell populations in patients with stage 0/1 chronic lymphocytic leukemia. Jounal of cancer therapy,2015,6,566-571. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Local Health District</ethicname>
      <ethicaddress>Room G71, East Wing
Edmund Blacket Bldg
Prince of Wales Hospital
Cnr High and Avoca streets
Randwick
NSW
2031</ethicaddress>
      <ethicapprovaldate>22/10/2013</ethicapprovaldate>
      <hrec>12/094</hrec>
      <ethicsubmitdate>25/06/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368185-final manuscript.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Terry Golombick</name>
      <address>level 3
Prichard Wing
St George Hospital
Gray street 
Kogarah
NSW
2217</address>
      <phone>+61 2 91132767</phone>
      <fax />
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Terry Golombick</name>
      <address>level 3
Prichard Wing
St George Hospital
Gray street 
Kogarah
NSW
2217</address>
      <phone>+61 2 91132767</phone>
      <fax />
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Terry Golombick</name>
      <address>level 3
Prichard Wing
St George Hospital
Gray street 
Kogarah
NSW
2217</address>
      <phone>+61 2 91132767</phone>
      <fax />
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>